Figure 1. Compounds 1 and 2 are well-known, previously reported PIM-1 inhibitors.

Compound 3 has been recently discontinued from Phase I clinical trials. These molecules bear an identical central core: imidazopyridazine. ^aIC₅₀ values were obtained as described in the Methods section.